Company news
Exicure, Inc. news in 2026
Exicure, Inc.'s news releases, calls and decks from 2026, newest first.
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement
September 16, 2026
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
August 3, 2026
Exicure Announces Board and Committee Changes
June 30, 2026
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
June 10, 2026
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
June 1, 2026
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
April 22, 2026
Exicure, Inc. Reports Full Year 2025 Financial Results
March 25, 2026
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
February 5, 2026
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
January 21, 2026